伊布替尼单药治疗慢性淋巴细胞白血病3项关键研究的长期安全性
该整合安全性分析纳入随机III期PCYC-1112(RESONATE,n=195)和PCYC-1115/1116(RESONATE-2,n=135)研究中的单药伊布替尼治疗患者,并在1b/2期PCYC-1102/1103研究(n=94,420 mg/d)中单独评估长期安全性。整合分析中伊布替尼治疗长达43个月,最常见不良事件主要为1/2级,随时间推移腹泻、疲乏、≥3级感染、出血和中性粒细胞减少的患病率呈下降趋势,高血压患病率升高但发生率在1年后下降。总体而言,长期伊布替尼治疗中不良事件以1/2级为主且可控。
要点
- 整合分析中伊布替尼治疗长达43个月,最常见不良事件为腹泻和疲乏,多为1/2级。
- 最常见3/4级不良事件为中性粒细胞减少(18%)和肺炎(12%)。
- 不良事件导致剂量减少者42例(13%),永久停药者37例(11%),多发生在第1年。
核心结论
- 在慢性淋巴细胞白血病患者长期伊布替尼治疗中,不良事件以1/2级为主且可控。
- 整合分析中随时间推移腹泻、疲乏、≥3级感染、出血和中性粒细胞减少的患病率呈下降趋势,高血压患病率升高但发生率在1年后下降。
- 不良事件导致的剂量调整主要发生在第1年,其后频率下降。
研究设计与样本
- 对随机III期PCYC-1112(RESONATE,n=195)和PCYC-1115/1116(RESONATE-2,n=135)研究中的单药伊布替尼治疗进行整合安全性分析。
- 在1b/2期PCYC-1102/1103研究(n=94,420 mg/d)中单独评估长期安全性。
- 整合分析中伊布替尼治疗长达43个月,PCYC-1102/1103长期随访中伊布替尼治疗长达67个月。
主要发现
- 整合分析中最常见不良事件主要为1/2级:腹泻173例(52%任何级别;15例,5%为3级)和疲乏119例(36%任何级别;10例,3%为3级)。
- 最常见3/4级不良事件为中性粒细胞减少60例(18%)和肺炎38例(12%)。
- 不良事件导致剂量减少42例(13%),永久停药37例(11%)。
- 导致停药的最常见不良事件(首选术语)包括肺炎4例、贫血3例和心房颤动3例。
- PCYC-1102/1103长期随访中3/4级不良事件与整合分析基本相似。
关键数值与推荐
- 整合分析中伊布替尼治疗长达43个月。
- PCYC-1102/1103研究中伊布替尼剂量为420 mg/d,治疗长达67个月。
临床怎么用
- 长期伊布替尼治疗中不良事件以1/2级为主且可控,剂量调整多发生在治疗第1年。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib, a first-in-class once-daily oral Bruton tyrosine kinase inhibitor indicated for chronic lymphocytic leukemia (CLL), is continued until progressive disease or unacceptable toxicity. We conducted an integrated safety analysis of single-agent ibrutinib from randomized phase 3 studies PCYC-1112 (RESONATE, n = 195) and PCYC-1115/1116 (RESONATE-2, n = 135), and examined longer-term safety separately in the phase 1b/2 PCYC-1102/1103 study (n = 94, 420 mg/d). In the integrated analysis (ibrutinib treatment up to 43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea (n = 173, 52% any-grade; n = 15, 5% grade 3) and fatigue (n = 119, 36% any-grade; n = 10, 3% grade 3). The most common grade 3/4 AEs were neutropenia (n = 60, 18%) and pneumonia (n = 38, 12%). Over time, prevalence of AEs of interest (diarrhea, fatigue, grade ≥3 infection, bleeding, and neutropenia) trended down; prevalence of hypertension increased, but incidence decreased after year 1. AEs led to dose reductions in 42 (13%) patients and permanent discontinuations in 37 (11%); dose modifications due to AEs were most common during year 1 and decreased in frequency thereafter. The most common AEs (preferred term) contributing to discontinuation included pneumonia (n = 4), anemia (n = 3), and atrial fibrillation (n = 3). With long-term follow-up on PCYC-1102/1103 (ibrutinib treatment up to 67 months), grade 3/4 AEs were generally similar to those in the integrated analysis. Overall, AEs were primarily grade 1/2 and manageable during prolonged ibrutinib treatment in patients with CLL. These trials were registered at www.clinicaltrials.gov as #NCT01578707, #NCT01722487, #NCT01724346, #NCT01105247, and #NCT01109069.
引用
- Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019. PMID: 31196847. doi:10.1182/bloodadvances.2018028761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。